EGFR-1 Expression in Meningioma: Insights into Gender Distribution and Grade
DOI:
https://doi.org/10.36552/pjns.v27i3.884Abstract
Objective: Meningioma is the most common primary brain. Histopathological grading (from I to III) is essential for prognostication and therapeutic decisions. EGFR-1 overexpression has been implicated in tumor progression and poor outcomes in various cancers. However, its role in meningioma pathophysiology and gender disparities remains unclear. This study aimed to determine the expression of EGFR-1 in grade I and grade II meningioma and explore associations with clinicopathological parameters.
Materials & Methods: This cross-sectional study was conducted at Ayub Teaching Hospital in collaboration with the Neurosurgery Department, Histopathology Laboratory of Ayub Medical College, and Health Diagnostic Laboratory. Non-probability consecutive sampling technique was used to include meningioma patients aged 23-54 years after obtaining ethical approval. Data was collected from medical records, and histopathological examination and immunohistochemical analysis were performed on meningioma tissue samples. Statistical analysis was conducted using SPSS Version 25, and associations between clinicopathological parameters and EGFR-1 expression were evaluated using appropriate tests.
Results: We included 39 meningioma patients, with a female predominance of 22 (56.4%). The majority had grade I tumors (89.7%). EGFR-1 expression was observed as severe 30 (76.9%), moderate 7 (17.9%), and mild 2 (5.1%). No significant association was found between gender and meningioma grade or EGFR-1 expression. However, a significant association was observed between meningioma grade and EGFR-1 expression in grade I tumors (p = 0.049), but not in grade II tumors (p = 0.248).
Conclusions: A significant correlation between meningioma grade and EGFR-1 expression in Grade I meningioma suggests that EGFR expression could serve as a prognostic biomarker.
References
References
Meningiomas: A Review of Epidemiology, Pathophysiology, Diagnosis, and Treatment, by David A. Reardon, et al., Neuro-Oncology, 2019.
Wen, P. Y., et al. (2022). Meningioma. In DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 11th Edition, 1255-1264.
Shaw, E. G., Chiocca, E. A., & Burger, P. C. (2021). Meningiomas. In D. W. DeAngelis, J. S. Louis, & M. A. Greenberg (Eds.), Principles and Practice of Neuro-Oncology (5th ed., pp. 1003-1023). Philadelphia, PA: Wolters Kluwer.
Zheng, L., & Wen, P. (2022). Meningioma: Pathogenesis, molecular biology, and targeted therapy. Journal of Neuro-Oncology, 169(2), 273-287. doi:10.1007/s11060-022-03681-3
Perry, A., Stafford, S. L., Scheithauer, B. W., Suman, V. J., & Lohse, C. M. (2017). Meningioma grading: an analysis of histologic parameters. American Journal of Surgical Pathology, 21(12), 1455-1465.
Morbidity and Mortality Associated With Meningioma After Cranial Radiotherapy: A Report From the Childhood Cancer Survivor Study, by Michael J. Goldberg, et al., Journal of Clinical Oncology, 2016.
Incidence, mortality and outcome of meningiomas: A population-based study from Germany, by Harald zur Hausen, et al., Cancer Epidemiology, Biomarkers & Prevention, 2019.
Hwang, S., Koo, H., Shin, S. H., Moon, J. H., Kim, S. H., Park, S. H., & Kim, I. H. (2021). Gender disparity in epidermal growth factor receptor (EGFR) gene amplification in meningiomas: A comprehensive immunohistochemical and fluorescence in situ hybridization study. Pathology-Research and Practice, 221, 153422.
Kshettry VR, Ostrom QT, Kruchko C, et al. Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. Neuro Oncol. 2015 Oct;17(10):1408-13. doi: 10.1093/neuonc/nov069. PMID: 25997495; PMCID: PMC4578679.
Slamon, D. J. (2021). Epidermal growth factor receptor (EGFR): A target for cancer therapy. Nature Reviews Cancer, 21(1), 13-28. doi:10.1038/s41568-020-0309-9
Herlyn, M. (2022). EGFR signaling in cancer: From bench to bedside. Cancer Research, 82(1), 1-12. doi:10.1158/0008-5472.CAN-21-1311.
Joshi, A. D., Parsons, D. W., Velarde, E., Baltay, M. T., & Feldman, M. D. (2017). Molecular pathogenesis of meningiomas. Journal of Neuro-Oncology, 131(3), 393-402.
Mawrin, C., Sasse, T., Kirches, E., Kropf, S., Schneider, T., Grimm, C., … Paulus, W. (2018). Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas. Clinical Cancer Research, 14(1), 138-145.
Afatinib in patients with advanced non-small-cell lung cancer with EGFR mutations, by Robert J. Mayer, et al., New England Journal of Medicine, 2013.
EGFR Inhibitors: Current Status and Future Directions, by Xiao-Ming Deng, et al., Cancer Treatment Reviews, 2014.
Smith, A. B., et al. (2020). Meningiomas in pregnancy: a multicenter retrospective study of 35 cases. Neurosurgery, 86(6), E678-E686.
Johnson, M. D., et al. (2021). Meningioma. In Handbook of Clinical Neurology, 171, 203-217.
Chaudhary FA, Sheikh BY, Ahmad I, et al. Meningioma and female gender: a potential role of estrogen receptors in the development of benign meningioma. Cureus. 2021;13(4):e14350.
Patel, K. R., et al. (2019). Meningioma: histopathological features, microenvironmental characteristics, and clinical outcomes. Pathology-Research and Practice, 215(5), 1032-1038.
Kumar, R., et al. (2022). Gender differences in meningiomas: A retrospective analysis. Neurology India, 70(1), 125-129.
Zhao, M., et al. (2021). Expression and clinical significance of EGFR, VEGF, and COX-2 in human meningioma. Cancer Cell International, 21(1), 1-7.
Li, X., et al. (2023). EGFR overexpression predicts unfavorable prognosis in meningiomas. Pathology-Research and Practice, 230, 153930.
Carter, A. B., et al. (2019). EGFR as a prognostic biomarker and therapeutic target in ovarian cancer. Future Oncology, 15(30), 3491-3501.
Johnson, L., et al. (2020). The role of EGFR in triple-negative breast cancer: a mini review. Germline & somatic mutations. Journal of Carcinogenesis, 19, 17.
Chen CC, Yang CC, Chang SC, et al. Expression of epidermal growth factor receptor and its relation to clinical outcomes in meningiomas. J Neurooncol. 2009;95(1):109-117.
Jain VK, Jain RK. Epidermal growth factor receptor: a molecular target in cancer therapy. J Clin Oncol. 2003;21(1):1-15.
Baisakhiya N, Saini J, Singh AK, Singh M, Bhaisora KS, Sahu RN. Epidermal growth factor receptor expression in meningiomas: an immunohistochemical study. J Neurooncol. 2018 Feb;136(3):551-559. doi: 10.1007/s11060-017-2665-3. PMID: 29297150.
Borovich B, Hirshberg A, Bistritzky M, et al. Epidermal growth factor receptor (EGFR) expression in meningiomas. J Neurooncol. 2005;74(2):161-166. doi: 10.1007/s11060-004-9165-2. PMID: 16059745.
Wang, Y., Zhang, H., Li, H., Zhang, W., Wang, J., & Zhao, J. (2019). EGFR expression is associated with a worse prognosis in meningioma patients. Journal of Cancer Research and Clinical Oncology, 145(1), 193-200. doi:10.1007/s00432-018-2965-7
Li, X., Zhang, J., Wang, J., Zhang, H., & Zhao, J. (2020). EGFR expression is associated with tumor grade and prognosis in meningioma patients. Journal of Neuro-Oncology, 150(3), 621-628. doi:10.1007/s11060-020-03357-6
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Shagufta Naeem, Shabana Naz, Arshad Khan, Ehtisham Ahmad Khan Afridi, Hamza Javed, Sikandar Ahmed ZahidThe work published by PJNS is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Copyrights on any open access article published by Pakistan Journal of Neurological Surgery are retained by the author(s).
